DOI: https://dx.doi.org/10.18203/issn.2455-4529.IntJResDermatol20221205
Published: 2022-04-26

A review article on Winlevi

Shaik Hafsa Kousar, T. V. L. Charishma Devi, V. Naveen

Abstract


Acne is a most common multiform skin condition. Androgen plays a major role in acne pathogenesis in both males and females. The appliance of anti-androgen is potentially effective. However, anti-androgens for topical application are not available in market. Clascoterone (cortexolone 17α propionate), an ester derivative of cortexolone is an androgen receptor inhibitor developed as a topical cream and solution for the treatment of androgen dependent skin disorders, including acne vulgaris. Although the mechanism of action of clascoterone (Winlevi) for topical treatment of acne vulgaris is not known. In 2020 clascoterone 1% has been first approved by United States of America (USA) for the topical therapy of acne vulgaris people aged 12 years or above. Assessment of acne is done based on overall severity of acne based on grades- grade 0, grade 1, grade 2, grade 3, and grade 4 (clear- severe). Both inflammatory on non-inflammatory lesions were counted. Treatment success is achieved when the grade or score is clear or almost clear. Clascoterone cream is well tolerated with no significant clinical safety issues. Clascoterone 1% twice daily treatment have the most effective favourable results with low adverse events. Currently first line treatment targeting aspects of acne includes benzyl peroxide topical or oral antibiotics, topical retinoid. Females with acne is treated with combined oral contraceptives (e. g. norgestimate and norethindrone are approved by FDA for treatment of acne in females) or spironolactone which affects androgens. Androgen receptors are present throughout the skin and found in sebaceous glands, dermal cells, and sebocytes. Androgen inhibiton is an effective way for treatment of acne in females.


Keywords


Acne, Clascotrone, Inhibition, Treatment, Phases

Full Text:

PDF

References


Hebert A, Thiboutot D, Gold LS, Cartwright M, Gerloni M, Fragasso E, Mazzetti A. Efficacy and Safety of Topical Clascoterone Cream, 1%, for Treatment in Patients With Facial Acne. 2020;1-10.

Dhillon S. Clascoterone: First Approval. Drugs. 2020;80(16):1745-50.

Tan JK, Bhate K. A global perspective on the epidemiology of acne. Br J Dermatol. 2015;172:3-12.

Cunliffe WJ, Gould DJ. Prevalence of facial acne vulgaris in late adolescence and in adults. Br Med J. 1979;1(6171):1109-10.

Thiboutot DM, Dréno B, Abanmi A, Alexis AF, Araviiskaia E, Barona Cabal MI, et al. Practical management of acne for clinicians: An international consensus from the Global Alliance to Improve Outcomes in Acne. J Am Acad Dermatol. 2018;78(2):S1-23.

Rocha MA, Bagatin E. Adult-onset acne: prevalence, impact, and management challenges. Clin Cosmet Investig Dermatol. 2018;11:59-69.

Elsaie ML. Hormonal treatment of acne vulgaris: an update. Clin Cosmet Investig Dermatol. 2016;9:241-8.

Adler BL, Kornmehl H, Armstrong AW. Antibiotic Resistance in Acne Treatment. JAMA Dermatol. 2017;153(8):810-1.

Lynn DD, Umari T, Dunnick CA, Dellavalle RP. The epidemiology of acne vulgaris in late adolescence. Adolesc Health Med Ther. 2016;7:13-25.

Highlights of prescribing information. 2020. Available at: https://www.winlevi.com/. Accessed on 24 January 2022.

Barbieri JS. A New Class of Topical Acne Treatment Addressing the Hormonal Pathogenesis of Acne. JAMA Dermatol. 2020;156(6):619-20.

Trifu V, Tiplica GS, Naumescu E, Zalupca L, Moro L, Celasco G. Cortexolone 17α-propionate 1% cream, a new potent antiandrogen for topical treatment of acne vulgaris. A pilot randomized, double-blind comparative study vs. placebo and tretinoin 0·05% cream. Br J Dermatol. 2011;165(1):177-83.

Eichenfield L, Hebert A, Gold LS, Cartwright M, Fragasso E, Moro L, et al. Open-label, long-term extension study to evaluate the safety of clascoterone (CB-03-01) cream, 1% twice daily, in patients with acne vulgaris. J Am Acad Dermatol. 2020;:83;477-85.

MPR. Winlevi Cream Approved for Acne Vulgaris. 2020. Available at: https://www.empr.com/home/ news/winlevi-clascoterone-cream-approved-topical-acnue-vulgaris/. Accessed on 24 January 2022.

Hebert AA, Thiboutot D, Gold LS, Cartwright M. Efficacy and Safety of Topical Clascoterone Cream, 1%, for Treatment in Patients With Facial Acne: Two Phase 3 Randomized Clinical Trials. JAMA Dermatol. 2020;156(6).

Redit. Acne Vulgaris improvement after two months of treatment, 2021. Available at: https://www.reddit.com/r/acne/comments/ecs0ha/acne_vulgaris_improvement_after_two_months_of/. Accessed on 24 January 2022.